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EXECUTIVE SUMMARY
The American College of Physicians (ACP) and the
Infectious Diseases Society of America (IDSA) have
jointly published 3 policy statements on AIDS, the first
in 1986 [1], the second in 1988 [2], and the third in
1994 [3]. In 2001, the IDSA created the HIV Medicine
Association (HIVMA), and this updated policy paper
is a collaboration between the ACP and the HIVMA
of the IDSA. Since the last statement, many new de-
velopments call for the need to reexamine and update
our policies relating to HIV infection. First, there have
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been major advances in treatment for HIV infection
that have transformed HIV/AIDS from a terminal ill-
ness to a chronic disease for many of those who have
access to potent therapies and expert medical care [4].
Second, there has been a profound expansion and in-
tensification of the global HIV pandemic, particularly
in sub-Saharan Africa, coupled with significant US lead-
ership and resources aimed at providing prevention and
care services to affected populations in developing
countries. Third, the concerns that were prevalent in
the mid-1990s regarding the possibility of HIV trans-
mission in health care settings have ultimately proven
to be unfounded as the result of the adoption of uni-
versal precautions in those settings.
In this article, we emphasize the public health and
clinical imperatives for earlier identification of persons
with HIV infection; the urgent need to expand access
to state-of-the-art HIV care and treatment for infected
individuals; the need for access to comprehensive pre-
vention and education for those living with and those
at risk for HIV infection; and the need for stronger
national leadership to respond to the HIV epidemic in
the United States and in the developing world.
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In December 2008, the ACP and HIVMA released a guidance
statement on screening for HIV infection in health care settings
that recommended that clinicians adopt routine screening for
HIV infection and encourage patients to be tested. Also in-
cluded in the guidance statement is a recommendation that
clinicians determine the need for additional screening on an
individual basis.
EPIDEMIOLOGY
Since the first AIDS cases were reported in 1981, ∼1.7 million
people have become infected with HIV in the United States
[5]. Of these individuals, 1550,000 have died, and nearly 1.2
million people are estimated to be living with the disease today
[6, 7]. Of these, 415,000 are estimated to be living with AIDS,
and 417,000 are estimated to be living with HIV infection.
Another 252,000–312,000 people are estimated to be living with
HIV infection or AIDS in the United States and to be unaware
of their status. In August 2008, the Centers for Disease Control
and Prevention (CDC) revised the annual HIV infection in-
cidence rate to 56,300 cases per year and asserted that this
number has remained stable for more than a decade [8].
In 2006, the largest estimated proportion of HIV/AIDS di-
agnoses in the United States were among men who have sex
with men [9], and a majority of those women who contracted
HIV infection did so through heterosexual contact [10]. HIV/
AIDS continues to disproportionately impact racial and ethnic
minorities, who now account for 65% of new AIDS cases [6].
During the mid-to-late 1990s, advances in treatment slowed
the progression of HIV infection to AIDS and dramatically
reduced the number of deaths among people living with AIDS.
Regionally, the South has had the greatest numbers of people
estimated to be living with AIDS, AIDS deaths, and new AIDS
diagnoses, followed by the Northeast, West, and Midwest [5,
6].
The number of pediatric AIDS cases has decreased consid-
erably in the United States, with only 38 cases diagnosed in
2006 (a considerable decrease from the ∼745 cases diagnosed
in 1995) [11]. Among children and adolescents, teenaged girls
and minorities have been particularly affected. Similar to the
adult population, children and adolescents have experienced a
dramatic decrease in morbidity and mortality due to HIV in-
fection in the United States since the advent of combination
antiretroviral therapy [12, 13].
Although the United States has seen a drastic decrease in the
number of AIDS-related deaths since the early 1990s, AIDS
remains a global epidemic and affects an estimated 33 million
people worldwide. The Joint United Nations Programme on
HIV/AIDS has estimated that, in 2007, 2.7 million persons were
newly infected with HIV, and there were 2 million AIDS-related
deaths globally. Sub-Saharan Africa continues to be the region
most affected by the AIDS pandemic and accounted for 67%
of all people living with HIV infection and 75% of AIDS-related
deaths in 2007. Although women represent 50% of people living
with HIV infection globally, they account for nearly 60% of
infections in sub-Saharan Africa, where transmission is pri-
marily through heterosexual contact. Nearly 90% of the 2 mil-
lion children !15 years of age living with HIV infection world-
wide are in sub-Saharan Africa, and 190% of the 270,000 deaths
due to AIDS among children in 2007 were in Africa [14].
HIV TREATMENT AND COMBINATION
ANTIRETROVIRAL THERAPY
More than a decade ago, combination antiretroviral therapy
was widely introduced in the United States and Europe, con-
stituting a medical breakthrough that revolutionized the treat-
ment of HIV infection in the developed world. The approval
of the first protease inhibitors in late 1995 and early 1996 shifted
medication strategies from monotherapy to combination ther-
apy with at least 2 different drug classes, and standardized
combination antiretroviral therapy came to be regarded as the
best clinical practice in treating HIV/AIDS. The effective sup-
pression of HIV through combination antiretroviral therapy
resulted in an 80% decrease in AIDS-related mortality in the
United States and in dramatic reductions in the prevalence of
the debilitating opportunistic infections that had been com-
monly associated with an AIDS diagnosis. It has been estimated
that combination antiretroviral therapy has saved 3 million life-
years [4].
For women with HIV infection, the availability of combi-
nation antiretroviral therapy has meant that they may become
pregnant and have children at virtually no risk to the baby if
there is appropriate administration of HIV treatment during
pregnancy and delivery and postnatal treatment for the infant
[15, 16]. Furthermore, in a recent study [17], pregnancy was
not associated with an increased risk for disease progression in
women who received combination antiretroviral therapy and
were not severely immunosuppressed. Such observations high-
light the remarkable impact of antiretroviral treatment and con-
tribute to the evidence in support of the right of women with
HIV infection to bear children.
There are now 32 US Food and Drug Administration–ap-
proved antiviral medications in 5 major drug classes [18]. More
recently, therapeutic breakthroughs have come in the form of
new classes of drugs with new methods of action against HIV
infection, as well as more potent medications in existing classes,
including combination products. For the patient, the toxicity
and adverse effects of many of the newer medications are re-
duced, compared with those of older drugs, and the pill burden
has also been substantially reduced, which promotes better ad-
herence to drug regimens.
Nonetheless, the development of drug resistance has become
a serious problem for long-term survivors of HIV infection,
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and a significant percentage of individuals with newly diagnosed
infection have contracted virus that is resistant to at least 1
major class of HIV medication. Drug resistance testing and
medication changes in response to the development of infection
with drug-resistant virus are an integral part of HIV care and
treatment. In addition to drug resistance, many patients who
receive antiviral treatment experience toxicities associated with
the long-term use of certain HIV drugs, including metabolic
changes, such as abnormal fat distribution, abnormal lipid and
glucose metabolism, and bone loss [19]. Finally, increases in
longevity have meant that many persons who are living with
HIV infection and are now middle aged are vulnerable to
chronic conditions that are associated with aging, some of
which are exacerbated by the presence of HIV infection.
In developing countries, access to combination antiretroviral
therapy is still a challenge, and when it is available, most in-
dividuals have access to only 1 drug regimen. A proliferation
of generic medications and deep discounts by pharmaceutical
companies have dramatically reduced the cost of first-line reg-
imens, but second-line therapies and common diagnostic tools
are still prohibitively expensive for many developing countries
and are not widely available in the public sector, where most
people receive their care. Opportunistic infections in HIV-in-
fected patients are common in developing countries, with tu-
berculosis being the leading cause of death among patients with
HIV infection in sub-Saharan Africa and in much of the de-
veloping world [20].
ACCESS TO CARE
HIV disease in the United States increasingly and dispropor-
tionately affects low-income and minority populations that are
less likely to have reliable access to care and that face many
other life challenges in addition to HIV infection, including
addiction and mental illness, as well as poverty, violence, ho-
mophobia, and racism. Early and reliable access to care is crit-
ical to successful treatment of HIV disease, but it is not well
supported by the fragmented US health care system. Moreover,
nearly 40% of newly diagnosed infections occur in persons who
are already severely immunosuppressed, which makes their
treatment more costly and less effective [21]. Recent studies
have estimated the annual cost of care for a person with a CD4+
cell count 1350 cells/mL to be $13,885, compared with $36,533
for an individual with a CD4+ cell count !50 cells/mL [22].
Treatment advances have resulted in a shift in medical re-
source utilization for patients with HIV infection from the
hospital to the outpatient setting. Early in the epidemic, many
HIV physicians were drawn to HIV medicine as interns and
residents when they cared for patients with HIV infection in
urban hospitals. Today, medical residents are far less likely to
be exposed to a large number of patients with HIV infection
during their training. In addition to this lost opportunity for
engagement, HIV medicine now requires expertise in primary
and specialty care, in addition to expertise in managing HIV
disease. The expanded knowledge base is necessary to manage
the serious coexisting conditions that people with HIV are de-
veloping as they live longer, such as diabetes, cardiovascular
disease, chronic pulmonary and renal disease, and hepatitis B
and C. In addition to an extensive medical knowledge base,
HIV medicine requires a special commitment to working in a
field that is poorly reimbursed and with a disease that largely
affects low-income and disenfranchised populations. All of
these factors have important implications for medical training
and for ensuring an adequate HIV clinician workforce.
The availability of experienced HIV clinicians is critical to
ensuring access to state of the art HIV treatment, and there
are already concerns about clinical capacity in many areas of
the United States—concerns that will only grow as the gen-
eration of physicians, physician assistants, and nurse practi-
tioners who entered the field of HIV medicine in the early days
of the epidemic begin to retire. Steps must be taken nationally
to ensure that an adequate number of trained HIV clinicians
continue to be available to care for the growing numbers of
HIV-infected individuals who are in need of care. It is partic-
ularly important to support minority physicians who are in-
terested in HIV medicine to reduce access and treatment dis-
parities for the black and Hispanic populations, which are
disproportionately affected by the disease [23].
PREVENTION IS CRITICAL
The HIV epidemic will not be eradicated by treatment alone,
but prevention efforts continue to lag far behind treatment
successes. We must focus on preventing new HIV infections
before they occur among our patients and on identifying pa-
tients with HIV/AIDS much earlier in the disease process. Pri-
mary care physicians may be in a unique position to identify
people with HIV/AIDS very early during the acute infection
stage. Within 2–4 weeks after exposure, 40%–90% of people
with acute HIV infection will experience symptoms similar to
those associated with other viral infections, such as infectious
mononucleosis or influenza [18]. Persons with acute HIV in-
fection are highly infectious. Nearly 50% of new HIV infections
can be attributed to people who transmitted the virus during
the acute infection stage [24]. Increasing the number of patients
who receive a diagnosis during the acute HIV infection stage
will help to connect them with treatment earlier and could play
an important role in reducing the number of new infections
in the community.
STIGMA PERSISTS
For too many in the United States, a diagnosis of HIV infection
still carries a significant stigma and can lead to discrimination
that impedes access to health insurance and health care pro-
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viders, jeopardizes employment, contributes to the high rates
of clinical depression among people with HIV/AIDS, and results
in people not entering care until their illness has advanced to
the point at which it is too late for them to fully benefit from
treatment [25–30]. Surveys confirm that prejudice and dis-
crimination associated with HIV infection are common, par-
ticularly among certain populations, such as African Americans
[31]. The stigma associated with HIV infection itself is com-
pounded by the racism and homophobia already experienced
by many of the most-affected populations. Strengthened basic
education efforts and campaigns are needed, along with lead-
ership from community, political, and medical authorities at
the local, state, and federal levels. Information on HIV trans-
mission and how it can be prevented must be accurate, honest,
and frequently communicated. Community and political sup-
port for scientifically proven prevention tools is imperative, not
only to prevent transmission, but also to reduce the stigma
associated with the behaviors that put people at increased risk
for HIV infection. Legal protections, such as health care cov-
erage for people with HIV/AIDS under the Americans with
Disabilities Act and antidiscrimination laws, together with
special programs, such as the Ryan White HIV/AIDS Treat-
ment Modernization Act (which provides access to HIV care
throughout the United States), are critical and still necessary
to mitigate the impact of the stigma still pervasive in many
communities across the United States.
Many patients with HIV/AIDS continue to feel that they
experience discrimination from health care providers, including
physicians [32]. These findings are supported anecdotally by
HIV medical providers, who have reported challenges obtaining
medical services outside of the HIV clinic for their patients. It
is important that we restate a policy from our previous policy
statements. All physicians, health care workers, and hospitals
have an ethical obligation to provide all patients, including
those with HIV/AIDS, with humane and competent care and
treatment.
POSITIONS OF THE HIVMA AND ACP
1. Federal and state governments should work to support
routine HIV testing for sexually active adults, pregnant
women, and newborns (when appropriate) through (1) cov-
erage and reimbursement by federally supported health care
programs and (2) elimination of requirements for a separate
informed consent for HIV testing.
In December 2008, the ACP and HIVMA released a guidance
statement on screening for HIV infection in health care settings
that recommended that clinicians adopt routine screening for
HIV infection and encourage patients to be tested. The state-
ment recommended that clinicians determine the need for ad-
ditional screening on an individual basis. In September 2006,
the CDC updated its recommendations for HIV testing in
health care settings to recommend routine HIV screening, and
yet federally supported health care programs have been slow
to support routine HIV screening through program and re-
imbursement policies. Routine HIV testing should be covered
as a preventive service under Medicare, and Medicaid programs
should be encouraged by the Centers for Medicare and Med-
icaid to add routine HIV screening to their state plans. Routine
HIV screening also should be encouraged and supported with
adequate resources through other federal programs, such as
community health centers, the Federal Bureau of Prisons, and
the Department of Veterans Affairs, as well as in the context
of health care reform.
HIV infection remains a serious concern among adolescents
and young adults, particularly among young men who have
sex with men, because of increases in new HIV infection di-
agnoses among this population [33]. HIV-infected adolescents
often have delayed entry into the health care system, but those
who receive a diagnosis at a medical site are more likely to
enter HIV care in a timely fashion [34]. Adolescents are more
likely to agree to be tested for HIV infection if it is recom-
mended by a physician [35]. There are a number of states that
allow minors to consent to screening and treatment, particu-
larly in the case of sexually transmitted infections. We support
modifications in state laws and regulations that would allow
minors to request or accept an offer of an HIV test without
parental consent.
2. Public health officials and others in public leadership
should promote evidence-based interventions, including en-
suring access to comprehensive sex education for children
and adolescents, wide availability of condoms and education
about their proper use, and broad availability of syringe ex-
change programs and drug treatment interventions, to min-
imize the risk of HIV transmission.
More than 25 years after the first cases of AIDS were reported
in the United States, we know a great deal about the behaviors
that put individuals at risk for contracting HIV infection and
about evidence-based interventions that reduce these risks. Phy-
sicians bear a special responsibility to assist persons in public
leadership positions to understand the basic facts about how
HIV can be transmitted, as well as the interventions that have
been demonstrated to reduce risky sexual or drug use behaviors.
Public education should include an emphasis on activities and
behaviors that do not transmit HIV, as well as those activities
that do.
For more than a decade, the federal government has provided
funding to states for abstinence-only education in public
schools that focuses on delaying sexual activity until marriage,
rather than on providing sound scientific information about
contraception and condom use as part of a comprehensive sex
education program [36–38]. These programs continue to be
funded, despite studies that have demonstrated that such pro-
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grams are unsuccessful in delaying sexual activity and provide
little sound information (and in some cases, provide misin-
formation) about how to reduce risky sexual activity that may
lead to unintended pregnancies or sexually transmitted infec-
tions, including HIV infection [39, 40].
Furthermore, interventions that have been shown to be ef-
fective in reducing HIV transmission among injection drug
users, including syringe and needle exchange or provision
programs and drug treatment programs, should be funded by
federal, state, and local government and be made widely avail-
able [41–43]. With injection drug use still accounting for a
significant number of new HIV infections, funding for drug
treatment interventions, especially in the public sector (and
including drug-free programs, as well as methadone, bupren-
orphine, and overdose-prevention programs) should be en-
hanced [44].
3. The US federal government should increase funding for
evidence-based HIV prevention activities through the CDC
to fund community-based programs aimed at populations at
high-risk and at groups with intermittent access to care, as
well as to enhance surveillance activities.
In fiscal year 2008, the CDC received $692 million for do-
mestic HIV/AIDS prevention activities [45]. There have been
no substantial increases in HIV prevention funding for do-
mestic programs in a number of years. This is despite the CDC’s
estimate that the number of new infections occurring annually
in the US has remained steady for a decade at 56,300 infections
per year. Although the CDC has developed new initiatives to
reduce HIV transmission rates—including a new emphasis on
ongoing prevention messages for HIV-positive patients, initia-
tives to target minority populations that are disproportionately
burdened with new infections, and recommendations to make
HIV testing routine and more widely available in medical set-
tings—more needs to be done [46–49]. In addition to these
new initiatives, HIV prevention funds are used for a wide range
of activities, including surveillance, prevention research, pro-
gram evaluation and policy development, and intervention ac-
tivities, including testing programs performed by state and local
governments and community-based organizations [50]. We be-
lieve that increased funding to support a comprehensive strat-
egy to reduce the incidence and prevalence of HIV infection
domestically is urgently needed.
4. Physicians and other health care professionals should
educate patients about all behaviors that put them at risk
for HIV infection and other sexually transmitted infections.
Physicians who treat patients with HIV infection should ed-
ucate their patients about eliminating behaviors that might
contribute to transmitting HIV infection to sexual and drug
use partners.
Physicians are in a unique position to influence the behaviors
of their patients and have a responsibility to incorporate ac-
curate and timely information on HIV infection and other
sexually transmitted infections into their clinical practices. Dis-
cussions with patients should convey an understanding of the
nature of the transmission of HIV infection and other sexually
transmitted infections; behaviors that might result in HIV
transmission and those that will not; the significance of a test
result positive for HIV antibodies; and guidelines for risk re-
duction, including the concept of “safer sex.”
Physicians should obtain complete sexual histories of their
adolescent and adult patients and should query them about
alcohol and other drug use. The need to modify sexual practices
to prevent transmission of infection should be discussed with
all patients, regardless of HIV infection status. Although some
studies have suggested that there is a decrease in high-risk
behavior following knowledge of one’s HIV infection status,
this finding has not been consistent for all populations. Other
studies have reported that the initial decrease in high-risk be-
havior may wane over time, which suggests that HIV infection
prevention for individuals who are HIV positive needs to be
reinforced throughout their lifetime [51, 52].
5. All people living with HIV/AIDS in the United States
should have access to HIV care provided by or in consul-
tation with individuals who are skilled in providing care for
HIV/AIDS. Physicians, hospitals, and other health care pro-
fessionals are obligated to provide state-of -the-art and hu-
mane care to patients with HIV infection or to arrange for
referral to an HIV expert. Adequate resources should be
dedicated to addressing the unique psychosocial needs of
newly identified patients in the health care setting. Funding
for HIV care should be adequate to maintain a competent
workforce. The Federal government should evaluate the ad-
equacy and capacity of the HIV clinical workforce.
As treatments and diagnostic methods have evolved over the
past decade, transforming HIV/AIDS from a terminal to a
chronic illness for many patients, clinical management of HIV
infection has become more complex. Thirty-two US Food and
Drug Administration–approved antiviral medications are avail-
able in 5 major drug classes and are prescribed in combination
drug regimens. Clinicians also must maintain knowledge about
the complex tests required to identify drug resistance patterns
and be prepared to address drug toxicities and manage co-
morbidities. The federal government maintains 17 HIV-related
guidelines and some, such as the HIV antiretroviral guidelines,
are updated frequently [18, 53].
Since the early days of the AIDS epidemic in the United
States, studies have demonstrated improved health outcomes
for those patients who are treated by clinicians who have larger
panels of patients with HIV infection and more experience in
treating HIV disease [54, 55]. Physicians who specialize in HIV
care and treatment come from the ranks of primary care med-
icine and infectious diseases sub-specialists.
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Many physicians who provide HIV care today were intro-
duced to HIV/AIDS during their residencies in major metro-
politan areas during the early days of the epidemic. As HIV
disease has moved from the hospital to the outpatient setting,
fewer young physicians are exposed to HIV medicine during
their internships and residencies. One study of medical resi-
dents from academic medical centers found that 58% of family
practice residents and 22% of internal medicine residents felt
“very unprepared” or “somewhat unprepared” to care for pa-
tients with HIV infection [56]. Moreover, reimbursement for
HIV care and treatment is generally poor. In a 2008 survey
conducted by HIVMA of clinics funded by the Ryan White
HIV/AIDS program, 69% of clinics reported difficulty recruit-
ing HIV clinicians and identified the top 2 challenges to re-
cruitment as lack of HIV clinicians and reimbursement issues
[57].
Resources are particularly needed to attract more minority
physicians to HIV medicine. With 3.3% of US physicians iden-
tifying as black and 2.8% identifying as Hispanic/Latino [58],
increasing physician diversity is an issue that requires serious
attention. This problem is not specific to HIV care, but to
medicine generally, as has been noted by the Institute of Med-
icine (IOM) and many others [59]. Special policies and pro-
grams are warranted to support minority physicians in pursuing
HIV medicine, given the disease’s significant impact on mi-
nority communities and the improved outcomes documented
for patients who are racially concordant with their physicians,
both for patients in general [60] and for patients with HIV
infection [61]. Because of the large federal investment in HIV
care and treatment and the move to routinize HIV testing in
health care settings [46], we call on the federal government to
evaluate the adequacy and capacity of the HIV clinical work-
force, both nationally and regionally.
6. The US government should work with states to assure
access to care for all patients with HIV/AIDS in the United
States by establishing a program that would provide com-
prehensive medical care and prescription drugs to all low-
income persons with HIV infection, as recommended by the
IOM. At a minimum, Congress should increase funding for
programs funded under the Ryan White Treatment Modern-
ization Act of 2006 and enact legislation that would allow
state Medicaid programs to expand eligibility to low-income
persons with HIV infection before such individuals experi-
ence progression to AIDS.
In fiscal year 2008, federal support for HIV care and treat-
ment was $11.6 billion, with 74% of these expenditures going
for the federal share of Medicaid and for Medicare [62]. Nev-
ertheless, HIV care and treatment is not accessible to all persons
living with HIV infection in the United States, and the avail-
ability of care and services varies significantly from state to
state. In 2004, the IOM conducted a Congressionally mandated
study of the financing and delivery of HIV care and treatment
for low-income uninsured and underinsured individuals with
HIV disease. They issued a report finding that nearly 50% of
individuals with HIV infection have no access or limited access
to HIV care and that the fragmentation of coverage from mul-
tiple funding sources was impeding sustained access to HIV
care [63]. The IOM recommended creating a new, federally
funded entitlement program to provide all low-income persons
with HIV infection access to a uniform set of primary care
benefits [63].
Despite evidence from HIV clinics across the country that
they are struggling to meet the medical needs of their patients
[64], Congress has neglected to adequately fund programs au-
thorized under the Ryan White Treatment Modernization Act
of 2006 or to pass federal legislation that would facilitate state
Medicaid coverage of low-income persons with HIV infection
[65, 66]. Under current Medicaid rules, in addition to having
a low income, eligible persons must be part of a specific cat-
egory of beneficiaries (i.e., must be a child, 165 years of age,
disabled, or a single parent). HIV infection itself is not an
eligibility category, and most persons with HIV/AIDS do not
qualify until they are disabled as a result of AIDS [67]. The
last several Congresses have failed to act upon federal legisla-
tion, referred to as the Early Treatment for HIV Act, that would
allow and encourage states, through enhanced federal matching
payments, to provide Medicaid coverage to single adults and
adolescents with HIV infection before they experience pro-
gression to AIDS [68].
In the absence of universal access to health care services for
all Americans, we support policies that ensure that all low-
income persons with HIV/AIDS have access to the standard of
care for HIV disease. The IOM proposal to create a federal
entitlement for the treatment of HIV infection would be the
most efficient and straightforward method to accomplish this
in the United States. In the absence of political will and ade-
quate federal revenues, we believe that Congress should respond
to the disparity in access to HIV care by increasing funding for
programs authorized under the Ryan White Treatment Mod-
ernization Act of 2006 and enacting the Early Treatment for
HIV Act.
7. Confidentiality of HIV-positive individuals should be
protected to the greatest extent possible, consistent with the
duty to protect others and to protect the public health.
Health care professionals must protect the confidentiality and
privacy of patients living with HIV disease. The confidentiality
of health care professionals who are themselves HIV-infected
must also be protected, and their HIV status should not be a
factor in evaluating job suitability or performance. Despite im-
provements in the public’s view of persons with HIV/AIDS and
laws and regulations outlawing discrimination, HIV/AIDS is
still a stigmatized disease, and public disclosure can have severe
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ramifications for individuals, including discrimination and vi-
olence [69, 70]. In addition to laws that protect the privacy of
all medical records, many states and localities have special con-
fidentiality laws and regulations that are relevant to HIV
infection.
Physicians must balance their responsibility to protect the
confidentiality of their patients with their duty to preserve the
health and welfare of their patient’s sexual or drug use partners.
In virtually all of the states and territories of the United States,
there are laws requiring health care professionals to report cases
of HIV infection to local or state health departments. Health
departments also assist health care professionals in counseling
patients about their duty to notify their sexual and drug use
partners about their potential HIV risk, and in many cases,
health department officials will actually provide the partner
with counseling and referral services. Partner counseling and
referral services are voluntary and confidential [71].
8. The US government should continue to support a com-
prehensive portfolio of research into the causes, prevention,
and treatment of HIV infection and AIDS, including research
aimed at identifying a vaccine, prevention technologies (in-
cluding barrier methods) to prevent HIV acquisition, the
development of improved antiretroviral therapies, and ther-
apeutic and prophylactic regimens for opportunistic infec-
tions and malignancies that affect persons with HIV infec-
tion. Additional research that evaluates the behavioral and
cultural aspects of prevention and treatment of HIV infection
in the US and the associated comorbidities should also be
well represented in the research agenda.
The National Institutes of Health is the global leader in AIDS
research, representing the largest and most significant public
investment in AIDS research in the world. The key themes of
the current AIDS research agenda at the National Institutes of
Health are a strong foundation in basic science, research to
prevent and reduce HIV transmission (including research into
vaccines, microbicides, and behavioral interventions), research
to develop better therapies for those who are already infected,
international research to address the pandemic in developing
countries, and biomedical and behavioral research to target the
disproportionate impact of AIDS on minority populations in
the United States [72]. In federal fiscal years 2007 and 2008,
the budget for AIDS research was $2.9 billion [73, 74].
US-supported AIDS research has accomplished a great deal,
from enhancing our understanding of the natural history of
HIV infection to catalyzing therapeutic developments that have
resulted in dramatic gains in life expectancy for infected in-
dividuals. A great deal more needs to be done. Prevention re-
search is vital, as is continuing research attention to the de-
velopment of medications with increased potency, better
resistance profiles, and less toxicity.
9. The US government should continue to devote sub-
stantial resources to respond to the global pandemic, with a
particular focus on developing countries. Resources should
be devoted to evidence-based prevention interventions, such
as risk-reduction programs for sexual transmission, condom
distribution, syringe and needle exchange, drug treatment
programs, and programs to prevent perinatal transmission;
antiretroviral treatment and comprehensive medical care and
support services for infants, children, and adults; and pro-
grams to provide care and services to children who have been
orphaned as a result of HIV. The US government should also
remain a major contributor to the Global Fund to Fight HIV,
Tuberculosis, and Malaria. US scientists, physicians, and
other experts should continue to assist and be supported in
the assistance of developing countries to address the oper-
ational, scientific, and training issues surrounding imple-
mentation of new programs.
Since 2003, the United States has played a major role in
addressing the global AIDS pandemic with the passage of the
President’s Emergency Program for AIDS Relief, which au-
thorized $15 billion over a 5-year period to battle HIV infection,
primarily in 15 focus countries [75]. In addition to providing
funding for prevention, treatment, and care programs, as well
as services for children orphaned by AIDS, the United States
also contributes to the Global Fund to Fight HIV, Tuberculosis
and Malaria.
From 2003 through March 2008, the number of individuals
who were receiving antiretroviral therapy in the 15 focus coun-
tries increased from 50,000 to 11.64 million [76]. We strongly
supported passage of the United States Global Leadership
Against HIV/AIDS, Tuberculosis, and Malaria Act in July 2008,
which reauthorized the US global AIDS program and author-
ized $48 billion in funding over a 5-year period for HIV, tu-
berculosis, and malaria programs [77]. We urge the US gov-
ernment to continue its robust commitment to global health
by funding the program at the levels recommended in the
legislation and maintaining and enhancing the US financial
support to the Global Fund to Fight HIV, Tuberculosis, and
Malaria.
10. Visitors with HIV infection should be able to enter the
United States, and otherwise qualified immigrants with HIV
infection should be able to obtain permanent residency status
or citizenship.
We are pleased that the statutory ban on persons with HIV
disease entering the United States as visitors or immigrants
ended with the signing of the United States Global Leadership
Against HIV/AIDS, Tuberculosis, and Malaria Act [77]. We now
urge the Secretary of Health and Human Services to move
expeditiously to remove HIV disease from the list of com-
municable diseases of public health significance and to end this
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long-standing discriminatory practice against visitors and im-
migrants with HIV infection.
CONCLUSIONS
There has been major progress in addressing the HIV epidemic,
both domestically and globally, but significant challenges exist,
and a great deal of work remains to be done. Continued support
is needed from both the public and private sectors for preven-
tion, education, basic and applied research, health services re-
search, and health care delivery. Federal, state, and local gov-
ernments must fill the leadership gaps in these areas. History
will judge us all by our individual and collective responses to
one of the worst pandemics the world has ever seen.
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